| Patient | Pierre Le Moyne d'Iberville |
|---|---|
| Date of birth | 1661-07-16 |
| Identifiers | MRN HR-ET014-SYN-TD; SSN (made up) 000-14-7260 |
| Document date | 2026-11-01 |
| Author | Marguerite Delacroix-Boateng, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient visit for recurrent fevers with chills after naval service in malaria-endemic areas, and an expected tropical deployment: history, examination, malaria testing, quantitative G6PD, and an infectious diseases (travel medicine) referral. Concerns: He fears another attack of fever at sea, where he would be far from a laboratory and responsible for the squadron; He must have every vaccine and certificate that entry to French Guiana and the islands requires before the squadron sails. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Chloroquine phosphate 500 mg tablet: 1,000 mg (two tablets) at once, then 500 mg at 6, 24 and 48 hours; take with food | 1,000 mg, then 500 mg at 6, 24 and 48 hours (2,500 mg salt in total) | Oral route | 1705-03-03 to 1705-03-05 | completed | S |
| Primaquine phosphate 26.3 mg tablet (15 mg base): two tablets (30 mg base) by mouth daily with food for 14 days | 30 mg base once daily for 14 days | Oral route | 1705-03-03 to 1705-03-16 | completed | S |
| Atovaquone-proguanil 250 mg/100 mg tablet: one tablet daily with food, starting one to two days before entering a malaria area, daily there, and for seven days after leaving | once daily from 1 to 2 days before until 7 days after the malaria areas | Oral route | 1705-10-13 | on-hold | S |
| Azithromycin 500 mg tablet: one tablet daily for up to three days for severe travelers' diarrhea (standby supply) | once daily for up to 3 days if needed | Oral route | 1705-10-13 | on-hold | S |
| Primaquine phosphate 26.3 mg tablet (15 mg base): two tablets (30 mg base) daily with food for 14 days, starting when he leaves the malaria areas (terminal prophylaxis) | 30 mg base once daily for 14 days after leaving the malaria areas | Oral route | 1705-10-13 | on-hold | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Advance care planning conversation, about 20 minutes | 1705-04-21 to 1705-04-21 | completed | S |
| Incision and drainage of a cutaneous abscess of the right forearm under local anesthesia, with wound culture | 1705-06-09 to 1705-06-09 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1705-04-21 | Tdap vaccine | completed | S |
| 1705-07-28 | Yellow fever vaccine, live, single dose; certificate (ICVP) issued, valid from ten days after vaccination | completed | S |
| 1705-07-28 | Hepatitis A vaccine, adult, dose 1 of 2 | completed | S |
| 1705-07-28 | Typhoid Vi polysaccharide vaccine | completed | S |
| 1705-07-28 | Hepatitis B vaccine (HepB-CpG), dose 1 of 2 | completed | S |
| 1705-10-13 | Hepatitis B vaccine (HepB-CpG), dose 2 of 2 | completed | S |
| 1705-10-13 | Influenza vaccine, inactivated, trivalent, preservative-free | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| late 1701 | An illness at sea, nature not recorded, that forced him to put in at port on a voyage to the Gulf of Mexico about three and a half years before intake | D (CLM-0007) |
| 1702 onward | Recurrent attacks of illness over the past three years, described by his biographer as malaria, that kept him from planned voyages | D (CLM-0008) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| He fears another attack of fever at sea, where he would be far from a laboratory and responsible for the squadron | active | S |
| He must have every vaccine and certificate that entry to French Guiana and the islands requires before the squadron sails | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 14.1 on 1705-10-13; Leukocytes [#/volume] in Blood by Automated count 5.6 on 1705-02-17; Platelets [#/volume] in Blood by Automated count 236 on 1705-10-13; Sodium [Moles/volume] in Serum or Plasma 139 on 1705-02-17; Potassium [Moles/volume] in Serum or Plasma 4.1 on 1705-02-17; Creatinine [Mass/volume] in Serum or Plasma 0.98 on 1705-02-17; Glucose [Mass/volume] in Serum or Plasma 92 on 1705-02-17; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 34 on 1705-02-17; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 29 on 1705-02-17; Bilirubin.total [Mass/volume] in Serum or Plasma 0.7 on 1705-03-31; Glucose-6-Phosphate dehydrogenase [Enzymatic activity/mass] in Red Blood Cells 11.8 on 1705-02-17; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1700)/1.73 sq M 98 on 1705-02-17; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 1705-04-21; Total score [AUDIT-C] 3 on 1705-04-21; Cholesterol [Mass/volume] in Serum or Plasma 192 on 1705-04-21; Cholesterol in HDL [Mass/volume] in Serum or Plasma 52 on 1705-04-21; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 116 on 1705-04-21; Triglyceride [Mass/volume] in Serum or Plasma 120 on 1705-04-21 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Recurrent episodes of fever with shaking chills and drenching sweats, three in the past two years, each beginning months after naval service in malaria-endemic areas; the first diagnosed as malaria abroad on a blood smear with the species not recorded and treated with chloroquine alone, the later two treated with chloroquine without testing; the last ended six weeks before intake; afebrile and well at intake; cause not established at intake; infectious diseases consultation requested | resolved | confirmed | R50.9 | S — Synthetic presenting problem anchored to his documented recurrent attacks of illness called malaria; superseded by the diagnosis at the infectious diseases consultation. |
| Relapsing Plasmodium vivax malaria: P. vivax DNA detected by PCR in blood drawn between attacks, with negative smears and rapid antigen test; after three relapses treated without antirelapse therapy; normal quantitative G6PD | resolved | confirmed | B51.9 | S — Synthetic modern diagnosis made at the infectious diseases consultation, linked to his documented recurrent attacks of illness called malaria; the species and the PCR result are synthetic. |
| Pre-travel care for a naval deployment, expected to sail early next year, to French Guiana and the French Antilles: yellow fever vaccination required for entry to French Guiana, malaria prevention, dengue, chikungunya and typhus prevention by vector avoidance, food and water safety, and travel vaccines | active | confirmed | Z71.84 | S — Synthetic modern counterpart of his documented preparation of a tropical campaign in 1705. |
| Small cutaneous abscess of the right forearm, about 2 cm, from a wooden splinter in the dockyard, without fever, spreading cellulitis or systemic signs; drained, without antibiotics; methicillin-susceptible Staphylococcus aureus on culture; resolved | resolved | confirmed | L02.413 | S — Synthetic acute problem; not a historical claim. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1705-02-17 | Hemoglobin [Mass/volume] in Blood | 13 | g/dL | 13.2-17.1 g/dL | Low | S |
| 1705-02-17 | Leukocytes [#/volume] in Blood by Automated count | 5.6 | 10*3/uL | 3.4-9.6 10*3/uL | Normal | S |
| 1705-02-17 | Platelets [#/volume] in Blood by Automated count | 141 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 1705-02-17 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 136-145 mmol/L | Normal | S |
| 1705-02-17 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1705-02-17 | Creatinine [Mass/volume] in Serum or Plasma | 0.98 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1705-02-17 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-99 mg/dL | Normal | S |
| 1705-02-17 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 34 | U/L | 7-52 U/L | Normal | S |
| 1705-02-17 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 29 | U/L | 13-39 U/L | Normal | S |
| 1705-02-17 | Bilirubin.total [Mass/volume] in Serum or Plasma | 1.1 | mg/dL | 0.3-1.2 mg/dL | Normal | S |
| 1705-02-17 | Glucose-6-Phosphate dehydrogenase [Enzymatic activity/mass] in Red Blood Cells | 11.8 | U/g{Hb} | 7-20.5 U/g{Hb} | Normal | S |
| 1705-02-17 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1700)/1.73 sq M | 98 | mL/min/{1.73_m2} | 60 or more | Normal | S |
| 1705-03-31 | Hemoglobin [Mass/volume] in Blood | 13.6 | g/dL | 13.2-17.1 g/dL | Normal | S |
| 1705-03-31 | Platelets [#/volume] in Blood by Automated count | 212 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1705-03-31 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.3-1.2 mg/dL | Normal | S |
| 1705-10-13 | Hemoglobin [Mass/volume] in Blood | 14.1 | g/dL | 13.2-17.1 g/dL | Normal | S |
| 1705-10-13 | Platelets [#/volume] in Blood by Automated count | 236 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1705-04-21 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 1705-04-21 | Total score [AUDIT-C] | 3 | {score} | S | ||
| 1705-04-21 | Cholesterol [Mass/volume] in Serum or Plasma | 192 | mg/dL | <=199 mg/dL | Normal | S |
| 1705-04-21 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 52 | mg/dL | >=40 mg/dL | Normal | S |
| 1705-04-21 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 116 | mg/dL | Below 130 | Normal | S |
| 1705-04-21 | Triglyceride [Mass/volume] in Serum or Plasma | 120 | mg/dL | <=149 mg/dL | Normal | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1705-02-17 | Body height | 175 | cm | S |
| 1705-02-17 | Body weight | 68.4 | kg | S |
| 1705-02-17 | Body mass index (BMI) [Ratio] | 22.3 | kg/m2 | S |
| 1705-02-17 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1705-02-17 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1705-02-17 | Heart rate | 70 | /min | S |
| 1705-02-17 | Respiratory rate | 14 | /min | S |
| 1705-02-17 | Body temperature | 36.7 | Cel | S |
| 1705-02-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1705-03-03 | Body height | 175 | cm | S |
| 1705-03-03 | Body weight | 68.6 | kg | S |
| 1705-03-03 | Body mass index (BMI) [Ratio] | 22.4 | kg/m2 | S |
| 1705-03-03 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1705-03-03 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1705-03-03 | Heart rate | 68 | /min | S |
| 1705-03-03 | Respiratory rate | 14 | /min | S |
| 1705-03-03 | Body temperature | 36.6 | Cel | S |
| 1705-03-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1705-03-31 | Body height | 175 | cm | S |
| 1705-03-31 | Body weight | 69 | kg | S |
| 1705-03-31 | Body mass index (BMI) [Ratio] | 22.5 | kg/m2 | S |
| 1705-03-31 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1705-03-31 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1705-03-31 | Heart rate | 66 | /min | S |
| 1705-03-31 | Respiratory rate | 14 | /min | S |
| 1705-03-31 | Body temperature | 36.6 | Cel | S |
| 1705-03-31 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1705-07-28 | Body height | 175 | cm | S |
| 1705-07-28 | Body weight | 69.4 | kg | S |
| 1705-07-28 | Body mass index (BMI) [Ratio] | 22.7 | kg/m2 | S |
| 1705-07-28 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1705-07-28 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1705-07-28 | Heart rate | 66 | /min | S |
| 1705-07-28 | Respiratory rate | 14 | /min | S |
| 1705-07-28 | Body temperature | 36.7 | Cel | S |
| 1705-07-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1705-10-13 | Body height | 175 | cm | S |
| 1705-10-13 | Body weight | 69.2 | kg | S |
| 1705-10-13 | Body mass index (BMI) [Ratio] | 22.6 | kg/m2 | S |
| 1705-10-13 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1705-10-13 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1705-10-13 | Heart rate | 64 | /min | S |
| 1705-10-13 | Respiratory rate | 14 | /min | S |
| 1705-10-13 | Body temperature | 36.6 | Cel | S |
| 1705-10-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1705-04-21 | Body height | 175 | cm | S |
| 1705-04-21 | Body weight | 69.2 | kg | S |
| 1705-04-21 | Body mass index (BMI) [Ratio] | 22.6 | kg/m2 | S |
| 1705-04-21 | Systolic blood pressure | 120 | mm[Hg] | S |
| 1705-04-21 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1705-04-21 | Heart rate | 64 | /min | S |
| 1705-04-21 | Respiratory rate | 14 | /min | S |
| 1705-04-21 | Body temperature | 36.6 | Cel | S |
| 1705-04-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1705-06-09 | Body height | 175 | cm | S |
| 1705-06-09 | Body weight | 69.3 | kg | S |
| 1705-06-09 | Body mass index (BMI) [Ratio] | 22.6 | kg/m2 | S |
| 1705-06-09 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1705-06-09 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1705-06-09 | Heart rate | 70 | /min | S |
| 1705-06-09 | Respiratory rate | 14 | /min | S |
| 1705-06-09 | Body temperature | 36.8 | Cel | S |
| 1705-06-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1705-02-17 | New patient visit for recurrent fevers with chills after naval service in malaria-endemic areas, and an expected tropical deployment: history, examination, malaria testing, quantitative G6PD, and an infectious diseases (travel medicine) referral | finished | S |
| 1705-03-03 | Two-week follow-up and infectious diseases consultation: PCR result and radical cure | finished | S |
| 1705-03-31 | Six-week review after chloroquine and primaquine: blood count, adverse effects, relapse surveillance | finished | S |
| 1705-07-28 | Pre-travel visit: yellow fever, hepatitis A, hepatitis B and typhoid vaccines, and the travel plan | finished | S |
| 1705-10-13 | Pre-departure review: no relapse, malaria chemoprophylaxis, vector, food and water precautions, standby treatment, and the plan on return | finished | S |
| 1705-04-21 | Periodic adult preventive visit | finished | S |
| 1705-06-09 | Same-day sick visit for a skin abscess of the right forearm | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Infectious diseases (travel medicine) consultation in two weeks to establish the cause of the recurrent fevers, advise on antirelapse treatment, and plan pre-travel care for the deployment | completed | GL-CDC-MAL-TX-2026, GL-IDSA-TRAVEL-2006 | S |
| Malaria testing between attacks: thick and thin blood smears, rapid antigen test, and Plasmodium species PCR sent to the reference laboratory; quantitative G6PD activity before any primaquine; blood count, kidney and liver tests | completed | GL-CDC-MAL-TX-2026 | S |
| Fever action plan: a blood smear the same day for any fever, at home, at sea or after travel; carry a card stating his malaria history | completed | GL-CDC-MAL-TX-2026, GL-YB-MAL-2026 | S |
| Chloroquine for the blood stage (1,000 mg salt, then 500 mg at 6, 24 and 48 hours) and primaquine 30 mg base daily for 14 days for radical cure, with the normal G6PD result; blood count and bilirubin after the course; report dark urine, breathlessness or blue lips | completed | GL-CDC-MAL-TX-2026 | S |
| Pre-travel plan for French Guiana and the Antilles: one dose of yellow fever vaccine with the certificate, hepatitis A, hepatitis B if not immune, typhoid; atovaquone-proguanil chemoprophylaxis for malaria areas; repellent, permethrin-treated clothing, screened or air-conditioned quarters and bed nets against mosquitoes, fleas, lice and mites; food and water precautions with standby azithromycin; primaquine terminal prophylaxis after leaving the malaria areas, and a malaria test for any fever after return | completed | GL-YB-YF-2026, GL-CDC-FG-2026, GL-YB-MAL-2026, GL-YB-DENGUE-2026, GL-YB-RICK-2026, GL-YB-TD-2026, GL-IDSA-TRAVEL-2006 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| No further malaria relapse in the six months after radical cure | 1705-10-13 | completed | No fever in the seven months since finishing primaquine | S |
| All required and recommended travel vaccines given, with a valid yellow fever certificate, at least ten days before departure | 1705-10-13 | completed | Yellow fever, hepatitis A dose 1, hepatitis B two-dose series, typhoid and influenza vaccines given; certificate valid | S |
| Knows to have a malaria test the same day for any fever, during travel and for months after return | 1705-03-31 | completed | Carries a fever card and explained the plan back correctly | S |